RecruitingNCT06937554

Evaluation of Functional and Nutritional Parameters in Fit Acute Leukemia Patients

Evaluation of Physical-cognitive-functional and Nutritional Parameters in Inpatients Affected by Acute Leukemia During Intensive Chemotherapy Treatment

Sponsor

University of Rome Tor Vergata

Enrollment

30 participants

Start Date

Apr 10, 2025

Study Type

OBSERVATIONAL

Conditions

Acute Leukemia

Summary

This single-center observational prospective longitudinal study will assess cognitive, physical, and nutritional performance in acute leukemia patients undergoing intensive chemotherapy. Patients will provide informed consent prior to enrollment. Hematologists will oversee clinical management and approve evaluations, while physical and rehabilitation medicine specialists and a nutritionist will conduct assessments. Performance will be evaluated at admission, discharge, and three weeks (21 days) after starting chemotherapy.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is monitoring the nutritional status and physical function of patients with acute leukemia (a fast-progressing blood cancer) who are undergoing intensive chemotherapy. The goal is to better understand how chemotherapy affects patients' strength, nutrition, and overall wellbeing so that care can be improved. **You may be eligible if...** - You are 18 or older - You have been diagnosed with acute leukemia - You are currently an inpatient receiving intensive chemotherapy - You have no restrictions on movement or physical activity - You are willing to sign the informed consent **You may NOT be eligible if...** - You are under 18 years old - You have a medical condition that your doctor believes would prevent you from safely completing study tasks Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.